Drugs / QBECO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05677113 | Aug 2023 → Feb 2027 expected | metastasis from malignant tumor of colon | Sunnybrook Health Sciences Centre | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QBECO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05677113 ↗ |
| Route | Subcutaneous | “0.1mL self-administered subcutaneous injections every 2 days” NCT05677113 ↗ |